- Home
- EOD vs OBIO Comparison
EOD vs OBIO Comparison
Compare EOD & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOD | OBIO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.3M | 246.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EOD | OBIO |
|---|---|---|
| Price | $6.37 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 128.8K | ★ 153.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $4.59 | $2.20 |
| 52 Week High | $6.42 | $5.42 |
Technical Indicators
Market Signals| Indicator | EOD | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.71 | 53.38 |
| Support Level | $5.56 | $4.02 |
| Resistance Level | N/A | $4.76 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 93.97 | 72.41 |
Price Performance
Historical ComparisonAbout EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.